WuXi Pharmatech Inc. ADR buy klostergang
Summary
This prediction ended on 07.12.15 with a price of €41.69. With a performance of 8.33%, the BUY prediction by klostergang for WuXi Pharmatech Inc. ADR closed with a slight gain. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| WuXi Pharmatech Inc. ADR | - | - | - | - |
| iShares Core DAX® | 0.000% | -2.064% | 13.111% | 16.685% |
| iShares Nasdaq 100 | 0.626% | -2.884% | 37.744% | 43.441% |
| iShares Nikkei 225® | 1.568% | -5.892% | 19.592% | 4.617% |
| iShares S&P 500 | 0.334% | -2.281% | 27.745% | 41.046% |
Comments by klostergang for this prediction
In the thread WuXi Pharmatech Inc. ADR diskutieren
WuXi PharmaTech
Shanghai-based WuXi PharmaTech is the leading China-based pharmaceutical and biotechnology R&D outsourcing company. As a research- driven and customer-focused company, WuXi PharmaTech provides pharmaceutical and biotechnology companies a broad and integrated portfolio of laboratory and research manufacturing services throughout the drug discovery and development process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug discovery and development by providing cost-effective and efficient outsourcing solutions that save its customers both time and money. Its operations are grouped into two segments: laboratory services, consisting of discovery chemistry, service biology, analytical, pharmaceutical development and process development services, and manufacturing, focusing on manufacturing of advanced intermediates and active pharmaceutical ingredients for R&D use.
30.10.2015: Gilead Sciences (NASDAQ:GILD) and WuXi PharmaTech (NYSE:WX) establish a strategic partnership to conduct analytical and stability studies of small molecule new chemical entities to support global marketing applications and commercial products.